Welcome to our dedicated page for PMGC Holdings news (Ticker: elab), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
PMGC Holdings Inc. (NASDAQ: ELAB) delivers innovative solutions across biopharmaceuticals, medical aesthetics, and strategic investments. This news hub provides investors with centralized access to all corporate announcements, regulatory updates, and market developments.
Track timely updates on clinical trial progress, partnership agreements, and financial performance. Find press releases covering engineered probiotic therapies for metabolic health, advancements in aesthetic medicine technologies, and strategic moves in fire prevention and energy sectors.
Our curated news collection enables informed decision-making through verified updates on FDA milestones, acquisition activity, and leadership changes. Bookmark this page for ongoing insights into ELAB's diversified growth strategy across healthcare and essential infrastructure markets.
PMGC Holdings Inc. (Nasdaq: ELAB) has announced a registered direct offering priced at-the-market under Nasdaq rules, aiming to raise approximately $1.48 million. The company has entered into definitive agreements with investors for the sale of 294,450 shares of common stock at $5.04 per share.
The offering includes pre-funded warrants with an exercise price of $0.001 per share. Following the offering, PMGC will have approximately 872,411 shares of common stock outstanding. The transaction is expected to close around March 24, 2025, subject to customary closing conditions.
Univest Securities, is serving as the sole placement agent for the offering, which is being conducted under a shelf registration statement on Form S-3 previously declared effective by the SEC on February 7, 2025.
PMGC Holdings (NASDAQ: ELAB) has announced the repurchase of shares from select existing shareholders who directly approached the company. The transactions' details are documented in Form 8-K filings available on sec.gov.
The company states it will evaluate additional share repurchase opportunities from other investors, subject to market conditions. Interested shareholders are instructed to submit written requests to PMGC's Newport Beach headquarters.
PMGC emphasizes this is not a formal share repurchase program or tender offer, and future repurchases remain at the company's discretion in response to unsolicited shareholder inquiries.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has scheduled a pre-IND meeting with the FDA for April 23, 2025 to discuss their novel obesity treatment EL-22. The therapy combines an engineered probiotic approach with GLP-1 receptor agonists, specifically targeting muscle preservation during weight loss.
EL-22 is designed to express myostatin on its surface, aiming to support muscle health through the myostatin pathway. The treatment has shown promising results in preclinical studies, including significant improvements in mdx mice studies published in 2022. Additionally, EL-22 has completed a Phase 1 clinical trial in South Korea, demonstrating general tolerability and safety in healthy volunteers.
Following FDA feedback, Northstrive plans to file an Investigational New Drug application in 2025 and begin clinical trials evaluating EL-22's combination with GLP-1 receptor agonists for obesity treatment.
PMGC Holdings (NASDAQ: ELAB) has announced a 1-for-7 reverse stock split effective March 10, 2025, to maintain Nasdaq listing compliance. The split will automatically consolidate every 7 shares of common stock into one share, with fractional shares rounded up to one full share.
The company's trading symbol will remain 'ELAB' but will receive a new CUSIP number (73017P201). Post-split, approximately 577,000 shares will be outstanding. All outstanding stock awards, options, warrants, and shares reserved for equity incentive plans will be proportionally adjusted.
This action comes in response to recent Nasdaq rule changes from January 17, 2025, which include stricter policies on delisting: automatic suspension for stocks below $0.10 for 10 consecutive days, removal of stay periods after second compliance periods, and limitations on reverse split frequencies.
PMGC Holdings Inc. (Nasdaq: ELAB) has announced its 2025 annual sponsorship of TCA Venture Group's Orange County network. TCA, one of the largest angel investor networks in the US, has invested over $300 million in 525+ companies, attracting $2.2 billion in follow-on investments.
PMGC manages three wholly owned subsidiaries: NorthStrive Biosciences (developing aesthetic medicines, including EL-22 for muscle preservation during weight loss), PMGC Research (R&D subsidiary utilizing Canadian research grants), and PMGC Capital (multi-strategy investment firm).
Through this sponsorship, PMGC will access TCA's national network of 400+ seasoned investors and professionals, enhancing its ability to identify investment and M&A opportunities while contributing to Southern California's business ecosystem.
PMGC Holdings (NASDAQ: ELAB) has provided an update on its capital structure, highlighting its debt-free status and strong financial position. The company currently has 4,042,295 common shares outstanding, with 4,931 stock options at a weighted-average exercise price of $304 per share, and 979,814 warrants at a weighted-average exercise price of $4.91.
Recent capital raises include an $8.0 million S-1 offering in September 2024 and a $1.9 million warrant inducement offering in January 2025. The company operates through three main subsidiaries: NorthStrive Biosciences (focused on aesthetic medicines), PMGC Research (utilizing Canadian research grants), and PMGC Capital (a multi-strategy investment firm).
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has submitted a pre-IND meeting request to the FDA for EL-22, a novel myostatin-targeting therapy designed to preserve muscle during weight loss treatments. The company expects a Type B pre-IND meeting with the FDA in Q2 2025 to discuss nonclinical studies and clinical development plans for EL-22's use in combination with GLP-1 receptor agonists for obesity treatment.
EL-22 is a patent-pending engineered probiotic that expresses myostatin on its surface. Preclinical studies in mdx mice showed significant physiological and functional improvements, and a Phase 1 trial in South Korea demonstrated general safety and tolerability in healthy volunteers. The company plans to file an IND application in 2025 to begin clinical trials evaluating EL-22's combination with GLP-1 receptor agonists.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), provided updates on its obesity drug candidates EL-22 and EL-32, designed to optimize fat loss while preserving muscle mass during weight loss therapies, including GLP-1 receptor agonists.
The company is preparing for a pre-IND meeting with the FDA in Q2 2025 for EL-22, a myostatin-engineered probiotic that has completed Phase 1 trials in South Korea showing general safety. Northstrive is currently seeking a U.S.-based cGMP manufacturing partner and aims to file an IND application in 2025.
For EL-32, a pre-clinical engineered probiotic expressing dual myostatin & activin-A inhibitors, Northstrive has engaged a CRO to conduct studies evaluating its effectiveness both alone and in combination with semaglutide in diet-induced obese mice.
PMGC Holdings (Nasdaq: ELAB) has announced that its subsidiary, PMGC Capital , has initiated portfolio building with strategic investments in fire prevention technology and U.S. uranium energy companies. The investments align with the company's strategy to finance innovation in essential industries with significant growth potential.
The uranium investments reflect PMGC's support for nuclear energy as a clean power source for reducing carbon emissions and meeting sustainable energy demands. In the fire prevention sector, PMGC has invested in a US-based company developing eco-friendly technologies to prevent fire ignition and spread.
The company commits to updating shareholders on portfolio expansion and will file required 13D SEC filings if any individual investment exceeds 4.9% ownership.
PMGC Holdings (NASDAQ: ELAB) announced that its subsidiary, Northstrive Biosciences, has signed a research agreement with a leading preclinical CRO to evaluate EL-32, a novel engineered probiotic, both alone and in combination with semaglutide for obesity treatment.
The study will assess EL-32's impact on glycemic control and body composition in diet-induced obese mice. EL-32 targets dual myostatin and activin-A pathways to preserve muscle mass during weight loss, addressing a significant limitation of current GLP-1 receptor agonists, which can cause 40-60% of weight loss to come from lean body mass.
The CRO will provide study results and a detailed report within three months of completion. Previous preclinical data has shown that EL-32 administration resulted in statistically significant improvements in physical muscular function and body composition.
FAQ
What is the current stock price of PMGC Holdings (elab)?
What is the market cap of PMGC Holdings (elab)?
